{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:46:24Z","timestamp":1792251984347,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["13537"],"award-info":[{"award-number":["13537"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-52098-8","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T21:03:04Z","timestamp":1725397384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-196X","authenticated-orcid":false,"given":"Anneke L.","family":"Eerkens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-450X","authenticated-orcid":false,"given":"Koen","family":"Brummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneg\u00e9","family":"Vledder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterre T.","family":"Paijens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8845","authenticated-orcid":false,"given":"Marta","family":"Requesens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-0068","authenticated-orcid":false,"given":"Dominik","family":"Loiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annechien","family":"Plat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris-Jan","family":"Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty","family":"Klok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-2203","authenticated-orcid":false,"given":"Refika","family":"Yigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Roelofsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha M.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-0511","authenticated-orcid":false,"given":"Rie","family":"Klomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-962X","authenticated-orcid":false,"given":"David","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"ter Elst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-1897","authenticated-orcid":false,"given":"Ren\u00e9","family":"Wardenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8403-474X","authenticated-orcid":false,"given":"Diana","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-3127","authenticated-orcid":false,"given":"Floris","family":"Foijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9206-4885","authenticated-orcid":false,"given":"Viktor Hendrik","family":"Koelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-8437","authenticated-orcid":false,"given":"Tjalling","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-071X","authenticated-orcid":false,"given":"Joost","family":"Bart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-9050","authenticated-orcid":false,"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-7816","authenticated-orcid":false,"given":"Anna K. L.","family":"Reyners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-9131","authenticated-orcid":false,"given":"Marco","family":"de Bruyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1821-3042","authenticated-orcid":false,"given":"Hans W.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"52098_CR1","unstructured":"Crosbie, E. J. et al. Seminar Endometrial Cancer. www.thelancet.com vol. 399 (1995)."},{"key":"52098_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"52098_CR3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.ejca.2011.11.014","volume":"48","author":"RA Nout","year":"2012","unstructured":"Nout, R. A. et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur. J. Cancer 48, 1638\u20131648 (2012).","journal-title":"Eur. J. Cancer"},{"key":"52098_CR4","first-page":"566","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 2020 26, 566\u2013576 (2020).","journal-title":"Nat. Med. 2020"},{"key":"52098_CR5","doi-asserted-by":"crossref","unstructured":"O'Malley, D.M.\u00a0et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J. Clin. Oncol. 40, 752\u2013761 (2022).","DOI":"10.1200\/JCO.21.01874"},{"key":"52098_CR6","first-page":"409","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (1979) 357, 409\u2013413 (2017).","journal-title":"Science (1979)"},{"key":"52098_CR7","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","volume":"28","author":"L Kist de Ruijter","year":"2022","unstructured":"Kist de Ruijter, L. et al. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial. Nat. Med 28, 2601\u20132610 (2022).","journal-title":"Nat. Med"},{"key":"52098_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"52098_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","volume":"567","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature 567, 525\u2013529 (2019).","journal-title":"Nature"},{"key":"52098_CR10","doi-asserted-by":"publisher","first-page":"e003329","DOI":"10.1136\/jitc-2021-003329","volume":"9","author":"R Muthuswamy","year":"2021","unstructured":"Muthuswamy, R. et al. CXCR6 by increasing retention of memory CD8 + T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J. Immunother. Cancer 9, e003329 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"52098_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.02.026","volume":"60","author":"HH Workel","year":"2016","unstructured":"Workel, H. H. et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur. J. Cancer 60, 1\u201311 (2016).","journal-title":"Eur. J. Cancer"},{"key":"52098_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","volume":"40","author":"CM Anadon","year":"2022","unstructured":"Anadon, C. M. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell 40, 545\u2013557.e13 (2022).","journal-title":"Cancer Cell"},{"key":"52098_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"52098_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/intimm\/dxh339","volume":"18","author":"C Goda","year":"2006","unstructured":"Goda, C. et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol. 18, 233\u2013240 (2006).","journal-title":"Int Immunol."},{"key":"52098_CR15","doi-asserted-by":"publisher","first-page":"e138772","DOI":"10.1172\/jci.insight.138772","volume":"5","author":"T Gruber","year":"2020","unstructured":"Gruber, T. et al. IL-32\u03b3 potentiates tumor immunity in melanoma. JCI Insight 5, e138772 (2020).","journal-title":"JCI Insight"},{"key":"52098_CR16","doi-asserted-by":"publisher","first-page":"e76339","DOI":"10.7554\/eLife.76339","volume":"11","author":"M Andreatta","year":"2022","unstructured":"Andreatta, M. et al. A CD4+ T cell reference map delineates subtype-specific adaptation during acute and chronic viral infections. Elife 11, e76339 (2022).","journal-title":"Elife"},{"key":"52098_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"52098_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"52098_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone, T. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat. Med 27, 504\u2013514 (2021).","journal-title":"Nat. Med"},{"key":"52098_CR20","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N. Engl. J. Med. 378, 1976\u20131986 (2018).","journal-title":"N. Engl. J. Med."},{"key":"52098_CR21","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med 24, 1655\u20131661 (2018).","journal-title":"Nat. Med"},{"key":"52098_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","volume":"15","author":"S Gao","year":"2020","unstructured":"Gao, S. et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J. Thorac. Oncol. 15, 816\u2013826 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"52098_CR23","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med 24, 1649\u20131654 (2018).","journal-title":"Nat. Med"},{"key":"52098_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948\u2013960 (2019).","journal-title":"Lancet Oncol."},{"key":"52098_CR25","doi-asserted-by":"crossref","unstructured":"Tong, B. C. et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non\u2013small cell lung cancer. in Journal of Thoracic and Cardiovascular Surgery vol. 163 427\u2013436 (Elsevier Inc., 2022).","DOI":"10.1016\/j.jtcvs.2021.02.099"},{"key":"52098_CR26","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med 25, 1706\u20131714 (2019).","journal-title":"Nat. Med"},{"key":"52098_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/path.5894","volume":"257","author":"MA Glaire","year":"2022","unstructured":"Glaire, M. A. et al. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. J. Pathol. 257, 340\u2013351 (2022).","journal-title":"J. Pathol."},{"key":"52098_CR28","doi-asserted-by":"crossref","unstructured":"Horeweg, N. et al. Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and portec-2 trials for early-stage endometrioid endometrial cancer. J Clin Oncol 41, 4369\u20134380 (2023).","DOI":"10.1200\/JCO.23.00062"},{"key":"52098_CR29","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","volume":"38","author":"A Leon-Castillo","year":"2020","unstructured":"Leon-Castillo, A. et al. Molecular classification of the PORTEC-3 Trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J. Clin. Oncol. 38, 3388\u20133397 (2020).","journal-title":"J. Clin. Oncol."},{"key":"52098_CR30","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/cncr.34025","volume":"128","author":"S Bellone","year":"2022","unstructured":"Bellone, S. et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 128, 1206\u20131218 (2022).","journal-title":"Cancer"},{"key":"52098_CR31","doi-asserted-by":"publisher","first-page":"S1284","DOI":"10.1016\/j.annonc.2023.10.037","volume":"34","author":"RN Eskander","year":"2023","unstructured":"Eskander, R. N. et al. LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin\/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial. Ann. Oncol. 34, S1284 (2023).","journal-title":"Ann. Oncol."},{"key":"52098_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ygyno.2023.08.015","volume":"177","author":"MD Toboni","year":"2023","unstructured":"Toboni, M. D. et al. Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 \u201cLynch-like\u201d mismatch repair gene mutation. Gynecol. Oncol. 177, 132\u2013141 (2023).","journal-title":"Gynecol. Oncol."},{"key":"52098_CR33","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang, M. M., Coupland, S. E., Aittokallio, T. & Figueiredo, C. R. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br. J. Cancer 2023 129, 1212\u20131224 (2023).","journal-title":"Br. J. Cancer 2023"},{"key":"52098_CR34","doi-asserted-by":"crossref","unstructured":"Bosse, T. et al. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int. J. Gynec. Cancer 33, ijgc-2022-004039 (2023).","DOI":"10.1136\/ijgc-2022-004039"},{"key":"52098_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer 2023 23, 295\u2013316 (2023).","journal-title":"Nat. Rev. Cancer 2023"},{"key":"52098_CR36","doi-asserted-by":"crossref","unstructured":"Olugbile, S. O. et al. Sustained oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy. 10.1200\/JCO.2017.35.15_suppl.3061 35, 3061\u20133061 (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.3061"},{"key":"52098_CR37","doi-asserted-by":"publisher","unstructured":"Puig-Saus, C. et al. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature (2023) https:\/\/doi.org\/10.1038\/s41586-023-05787-1.","DOI":"10.1038\/s41586-023-05787-1"},{"key":"52098_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","volume":"57","author":"A Franken","year":"2024","unstructured":"Franken, A. et al. CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity 57, 541\u2013558.e7 (2024).","journal-title":"Immunity"},{"key":"52098_CR39","doi-asserted-by":"publisher","first-page":"e1588085","DOI":"10.1080\/2162402X.2019.1588085","volume":"8","author":"T Matsuda","year":"2019","unstructured":"Matsuda, T. et al. TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. Oncoimmunology 8, e1588085 (2019).","journal-title":"Oncoimmunology"},{"key":"52098_CR40","doi-asserted-by":"publisher","unstructured":"Pai, J. A. et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell (2023) https:\/\/doi.org\/10.1016\/j.ccell.2023.03.009.","DOI":"10.1016\/j.ccell.2023.03.009"},{"key":"52098_CR41","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1136\/jitc-2021-003325","volume":"10","author":"S Jiao","year":"2022","unstructured":"Jiao, S. et al. Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling. J. Immunother. Cancer 10, 3325 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"52098_CR42","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"52098_CR43","doi-asserted-by":"publisher","unstructured":"Mandard, A.M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma clinicopathologic correlations. https:\/\/doi.org\/10.1002\/1097-0142.","DOI":"10.1002\/1097-0142"},{"key":"52098_CR44","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff, M. T. et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann. Oncol. 29, 1861\u20131868 (2018).","journal-title":"Ann. Oncol."},{"key":"52098_CR45","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell, T. R. et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29, 1853\u20131860 (2018).","journal-title":"Ann. Oncol."},{"key":"52098_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"52098_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal complementary data sources and analysis options. Sci. Signal 6, 1\u201320 (2013).","journal-title":"Sci. Signal"},{"key":"52098_CR48","doi-asserted-by":"publisher","unstructured":"de Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res (2023) https:\/\/doi.org\/10.1158\/0008-5472.can-23-0816.","DOI":"10.1158\/0008-5472.can-23-0816"},{"key":"52098_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21671-w","volume":"12","author":"CG Urz\u00faa-Traslavi\u00f1a","year":"2021","unstructured":"Urz\u00faa-Traslavi\u00f1a, C. G. et al. Improving gene function predictions using independent transcriptional components. Nat. Commun. 12, 1464 (2021).","journal-title":"Nat. Commun."},{"key":"52098_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GXY Zheng","year":"2017","unstructured":"Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"52098_CR51","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"52098_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N. & Bormann, N. L. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. F1000Res 9, 47 (2020).","journal-title":"F1000Res"},{"key":"52098_CR53","doi-asserted-by":"publisher","unstructured":"Ryan, N. A. J. et al. Histological and somatic mutational profiles of mismatch repair deficient endometrial tumours of different aetiologies. (2021) https:\/\/doi.org\/10.3390\/cancers.","DOI":"10.3390\/cancers"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52098-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52098-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T22:02:14Z","timestamp":1725400934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52098-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52098"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52098-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HWN and MB received grants from the Dutch Cancer Society (KWF), the European Research Council (ERC), Health Holland (HH), Mendus, BioNovion, Aduro Biotech, Vicinivax, Genmab and IMMIOS (all paid to the institute); received non-financial support from BioNTech, Surflay Nanotec and Merck Sharp & Dohme; are stock option holders in Sairopa. DC reports to be part of the advisory board for Merck Sharp & Dohme, his immediate family member is an Amgen employee, and received funding from HalioDx, unrelated to the subject of this manuscript. VHK served as an invited speaker on behalf of Sharing Progress in Cancer Care (SPCC) and Indica Lab, reports to be part of the advisory board of Takeda, and has sponsored research agreements with Roche and IAG, all unrelated to the current trial. TB received grants from the Dutch Cancer Society, unrelated to the subject of this manuscript. JB received grants from the Dutch Cancer society and AstraZeneca. MJ reports to be part of the advisory board of Pierre Fabre, AstraZeneca, BMS, and GSK. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7695"}}